Dexpanthenol

FDA’s June 2024 list of off-patent, off-exclusivity drugs sees rise in cancer, HIV treatments

This week PharmaCompass brings to you key highlights of the US Food and Drug Administration’s

US DMF filings indicate a robust API industry, with multiple first-to-file challenges

This week, PharmaCompass brings you a compilation of the Drug Master Files (DMFs) updates at